Century Therapeutics Stock Forecast

Stock Price Forecast

According to 5 analysts polled by S&P Global, Century Therapeutics stock has a consensus rating of "Buy" and an average price target of $4.75. The average 1-year stock price forecast is 105.63% higher than the current stock price, while the lowest is $2.00 (-13.42%) and the highest is $8.00 (+246.32%).

Price Target: $4.75 (+105.63%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$2.00	$4.75	$4.50	$8.00
Change	-13.42%	+105.63%	+94.81%	+246.32%

Analyst Ratings

The average analyst rating for Century Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	2	3	1	2	3	3
Buy	1	1	1	1	1	1
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	5	3	4	5	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Salim Syed Mizuho Securities	Mizuho Securities	Buy Maintains $8	Buy	Maintains	$8	+246.32%	Jun 10, 2026
Phil Nadeau TD Cowen	TD Cowen	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Jun 9, 2026
Edward Tenthoff Piper Sandler	Piper Sandler	Buy Reiterates $4	Buy	Reiterates	$4	+73.16%	Jun 9, 2026
Mitchell Kapoor H.C. Wainwright	H.C. Wainwright	Buy Reiterates $5	Buy	Reiterates	$5	+116.45%	May 26, 2026
William Maughan Clear Street	Clear Street	Buy Maintains $6.6	Buy	Maintains	$6.6	+185.71%	Mar 12, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

from 109.16M

-100.00%

from 109.16M

Revenue Next Year

n/a

EPS This Year

-0.46

from -0.03

EPS Next Year

-0.46

from -0.46

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	5.20M	2.24M	6.59M	109.16M	-
Revenue Growth	-	-	-57.01%	194.81%	1,556.76%	-100.00%
Operating Income	-94.88M	-123.83M	-125.18M	-135.17M	-15.04M	-102.27M
Net Income	-95.82M	-130.93M	-136.67M	-126.57M	-9.58M	-92.82M
EPS	-	-	-	-	-0.03	-0.46
Free Cash Flow	-96.45M	-79.59M	-71.09M	49.44M	-97.21M	-138.00M
No. Analysts	-	-	-	-	-	5

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2026	2027	2028
High	-100.0%
Avg	-100.0%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-0.37
Avg	-0.46
Low	-0.55

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-